Cyclooxygenase expression in splanchnic hyposensitivity to glypressin of bleeding portal hypertensive rats

European Journal of Clinical Investigation

Volumn 33, Issue 6, 2003, Pages 505-512

  Huang, H C ^a,c   Wang, S S ^b,c   Chen, Y C ^a,c   Lee, Fa Yauh ^a,c   Chang, F Y ^a,c   Lin, H C ^a,c   Hou, M C ^a,c   Chan, C C ^a,c   Chen, C T ^a,c   Wu, S L ^b,c   Lee, S D ^a,c  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b TAIPEI MUNICIPAL GAN DAU HOSPITAL   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Cyclooxygenase; Glypressin; Portal hypertension; Prostacyclin; Splanchnic hyposensitivity

Indexed keywords

6 OXOPROSTAGLANDIN F1 ALPHA; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; MESSENGER RNA; TERLIPRESSIN;

ABDOMINAL AORTA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTONOMIC NERVOUS SYSTEM; BLEEDING; BLOOD SAMPLING; CONTROLLED STUDY; DRUG EFFECT; DRUG SENSITIVITY; HEMODYNAMICS; INFUSION; MALE; NONHUMAN; PORTAL HYPERTENSION; PORTAL VEIN; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSTAGLANDIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; SUPERIOR MESENTERIC ARTERY; VEIN LIGATION;

ANIMALS; CYCLOOXYGENASE INHIBITORS; HEMODYNAMIC PROCESSES; HEMORRHAGE; HYPERTENSION, PORTAL; LYSINE VASOPRESSIN; MALE; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SPLANCHNIC CIRCULATION;

EID: 0038575758     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.2003.01162.x     Document Type: Article

References (47)

1. D'Amico G, Pagliaro L, Bosch J. The treatment of portal hypertension: a meta-analytic review. Hepatology 1995;22:332-54.
2. Valla D, Geoffroy P, Girod C, Lebrec D. Circulatory actions of vasopressin in anaesthetized rats with portal hypertension subjected to haemorrhage. J Hepatol 1986;2:328-39.
3. Kravetz D, Cummings SA, Groszmann RJ. Hyposensitivity to vasopressin in a hemorrhage-transfused rat model of portal hypertension. Gastroenterology 1987;93:170-5.
4. Valla D, Girod C, Lee SS, Braillon A, Lebrec D. Lack of vasopressin action on splanchnic hemodynamics during bleeding: a study in conscious, portal hypertensive rats. Hepatology 1988;8:10-5.
5. Tsai YT, Lee FY, Lin HC, Lee SD, Hsia HC, Lin WJ et al. Hyposensitivity to vasopressin in patients with hepatitis B-related cirrhosis during acute variceal bleeding. Hepatology 1991;13:407-12.
6. Chu CJ, Lee FY, Wang SS, Chang FY, Lin HC, Hou MC et al. Aminoguanidine ameliorates splanchnic hyposensitivity to glypressin in a haemorrhage-transfused rat model of portal hypertension. Clin Sci 1998;95:629-36.
7. Paller MS, Linas SL. Role of angiotensin II, alpha-adrenergic system and arginine vasopressin on arterial pressure in the rat. Am J Physiol 1984;246:H25-30.
8. Haddy FT, Scott JB, Molnar JI. Mechanism of Volume replacement and vascular constriction following haemorrhage. Am J Physiol 1965;208:169-81.
9. Sitzmann JV, Li SS, Lin PW. Prostacyclin mediates splanchnic vascular response to norepinephrine in portal hypertension. J Surg Res 1989;47:208-11.
10. Wu Y, Li SS, Campbell KA, Sitzmann JV. Modulation of splanchnic vascular sensitivity to angiotensin II. Surgery 1991;110:162-8.
11. Dusting GJ, Moncada S, Vane JR. Vascular actions of arachidonic acid and metabolites in perfused mesenteric and femoral beds of the dog. Eur J Pharmacol 1978;49:65-72.
12. Reed MK, Taylor BJ, Smith G, Phan T, Myers SI. Splanchnic prostanoid production: effect of hemorrhagic shock. J Surg Res 1990;48:579-83.
13. Hernandez R, Myers I. Prostacyclin regulates splanchnic blood flow during early hemorrhage/reperfusion injury. Prostag Leukotr Ess 1993;48:401-5.
14. 2 release following acute hemorrhage is due to new protein synthesis. Prostag Leukotr Ess 1993;48:207-10.
15. Lee FY, Chu CJ, Wang SS, Chang FY, Lin HC, Hou MC et al. Inhibition of prostacyclin by indomethacin ameliorates the splanchnic hyposensitivity to glypressin in haemorrhage-transfused common bile duct-ligated rats. Eur J Clin Invest 2001;31:145-53.
16. Wang SS, Chu CJ, Lee FY, Wu SL, Lin HC, Chan CC et al. Effects of prostacyclin inhibition on splanchnic hyposensitivity to glypressin in a hemorrhage-transfused rat model of portal hypertension. Scand J Gastroenterol 2000;35:426-32.
17. Chojkier M, Groszmann RJ. Measurement of the portal-systemic shunting in the rat by using γ-labeled microspheres. Am J Physiol 1981;240:G371-5.
18. Lee FY, Colombato LA, Albillos A, Groszmann RJ. Administration of ω-nitro-L-arginine ameliorates portal-systemic shunting in portal-hypertensive rats. Gastroenterology 1993;105:1464-70.
19. Lee FY, Wang SS, Tsai YT, Lin HJ, Chu CJ, Wu SL et al. Aminoguanidine corrects hyperdynamic circulation without ameliorating portal hypertension and portal hypertensive gastropathy in anesthetized portal hypertensive rats. J Hepatol 1997;26:687-93.
20. Chirgwin JM, Pryzbyla RJ, McDonald RJ, Rutter WJ. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry 1979;18:5294-9.
21. Chamberlain LH, Buroyne RD. Identification of a novel cysteine string protein variant and expression of cysteine string proteins in non-neuronal cells. J Biol Chem 1996;271:7320-3.
22. Lee SH, Soyoola E, Chanmugam P, Hart S, Sun W, Zhong H et al. Selective expression of mitogen-inducible cyclooxygenase in macrophages stimulated with lipopolysaccharide. J Biol Chem 1992;267:25934-8.
23. Tanoue K, Ohta M, Tarnawski AS, Wahlstrom KJ, Sugimachi K, Sarfeh IJ. Portal hypertension activates the nitric oxide synthase genes in the esophageal mucosa of rats. Gastroenterology 1996;110:549-57.
24. Chu CJ, Wu SL, Lee FY, Wang SS, Chang FY, Lin HC et al. Splanchnic hyposensitivity to glypressin in a haemorrhage/transfused rat model of portal hypertension: role of nitric oxide and bradykinin. Clin Sci 2000;99:475-82.
25. Guarner C, Soriano G, Such J, Teixidó M, Ramis I, Bulbena O et al. Systemic prostacyclin in cirrhotic patients. Relationship with portal hypertension and changes after intestinal decontamination. Gastroenterology 1992;102:303-9.
26. 2 and glucagon levels in humans. Ann Surg 1993;217:248-52.
27. Oberti F, Sogni P, Cailmail S, Moreau R, Pipy B, Lebrec D. Role of prostacyclin in hemodynamic alterations in conscious rats with extrahepatic and intrahepatic portal hypertension. Hepatology 1993;18:621-7.
28. Hamilton G, Rosza I, Hutton R, Chow FPR, Dandona P, Hobbs KE. Portal vein prostacyclin activity in experimental portal hypertension in rats. Clin Sci 1981;61:327-9.
29. 2) in the feline mesenteric vascular bed. Arch Int Pharmacodyn Ther 1979;241:214-23.
30. Wu Y, Burns C, Campbell KA, Sitzmann JV. Systemic and portal prostacyclin and thromboxane response to hemorrhage in portal hypertension. Shock 1994;2:68-71.
31. Reed MK, Taylor B, Myers SI. The effect of hypoxia on rat splanchnic prostanoid output. Prostaglandins 1989;38:599-608.
32. 2 from the splanchnic bed. J Trauma 1990;30:993-9.
33. Herschman AW. Prostaglandin synthase 2. Biochim Biophys Acta 1996;1299:125-40.
34. Smith W-L, De Witt DL. Biochemistry of prostaglandin endoperoxide H synthase-1 and synthase-2 and their differential susceptibility to nonsteroidal anti-inflammatory drugs. Semin Nephrol 1995;15:179-94.
35. Potenza MA, Botrugno OA, De Salvia MA, Lerro G, Nacci C, Marasciulo FL et al. Endothelial COX-1 and -2 differentially affect reactivity of MVB in portal hypertensive rats. Am J Physiol 2002;283:G587-94.
36. Hou MC, Cahill PA, Zhang S, Wang YN, Hendrickson RJ, Redmond EM et al. Enhanced cyclooxygenase-1 expression within the superior mesenteric artery of portal hypertensive rats: role in the hyperdynamic circulation. Hepatology 1998;27:20-7.
37. Zebre RL, Bayorh MA, Feuerstein G. Vasopressin: an essential pressor factor for blood pressure recovery following hemorrhage. Peptides 1982;3:509-14.
38. Chien S. Role of the sympathetic nervous system in hemorrhage. Physiol Rev 1967;47:214-88.
39. Pizcueta P, Piqué JM, Ferndndez M, Bosch J, Rodés J, Whittle BJ et al. Modulation of the hyperdynamic circulation of cirrhotic rats by nitric oxide inhibition. Gastroenterology 1992;103:1909-15.
40. Sitzmann JV, Bulkley GB, Mitchell MC, Campbell K. Role of prostacyclin in the splanchnic hyperemia contributing to portal hypertension. Ann Surg 1989;209:322-7.
41. Bruix J, Bosch J, Kravetz D, Mastai R, Rodéz J. Effects of prostacychn inhibition on systemic and hepatic hemodynamics in patients with cirrhosis of the liver. Gastroenterology 1985;88:430-5.
42. Lee FY, Albillos A, Colombato LA, Groszmann RJ. The role of nitric oxide in the vascular hyporesponsiveness to methoxamine in portal hypertensive rats. Hepatology 1992;16:1043-8.
43. Sieber CC, Groszmann RJ. In vitro hyporeactivity to methoxamine in portal hypertensive rats: reversal by nitric oxide inhibition. Am J Physiol 1992;262:G996-1001.
44. Huang HC, Chu CJ, Lee FY, Chang FY, Wang SS, Lin HC et al. Chronic inhibition of nitric oxide ameliorates splanchnic hyposensitivity to glypressin in a hemorrhage-transfused rat model of portal hypertension. Scand J Gastroenterol 2000;35:1308-13.
45. Gayoto LC, Guzman J, Brito EM, Mies S, Pontieri V, Raia S et al. Brakykinin release into portal blood during hemorrhagic shock. J Physiol 1979;292:80-1.
46. 9-brakykinin and bradykinin. J Pharmacol Exp Ther 1993;264:930-7.
47. Mombouli JV, Bissiriou I, Agboton V, Vanhoutte PM. Endothelium-derived hyperpolarizing factor: a key mediator of the vasodilator action of bradykinin. Immunopharmacology 1996;33:46-50.